NO20060313L - Saquinavirmesylat oral doseringsform - Google Patents

Saquinavirmesylat oral doseringsform

Info

Publication number: NO20060313L
Authority: NO; Norway
Prior art keywords: mesylate; sakinavir; dosage form; oral dosage; saquinavir mesylate
Prior art date: 2003-07-11

Application number

NO20060313A

Other languages

English (en)

Norwegian (no)

Inventor

Martin Howard Infeld

Antonio A Albano

Navnit Hargovindas Shah

Wantanee Phuapradit

Lin Zhang

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-11

Filing date

2006-01-20

Publication date

2006-02-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34068244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060313(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-01-20 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2006-02-09 Publication of NO20060313L publication Critical patent/NO20060313L/no

Links

IRHXGOXEBNJUSN-YOXDLBRISA-N Saquinavir mesylate Chemical compound CS(O)(=O)=O.C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 IRHXGOXEBNJUSN-YOXDLBRISA-N 0.000 title 1
239000006186 oral dosage form Substances 0.000 title 1
229960003542 saquinavir mesylate Drugs 0.000 title 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 5
239000007884 disintegrant Substances 0.000 abstract 2
239000011230 binding agent Substances 0.000 abstract 1
239000012458 free base Substances 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
239000007892 solid unit dosage form Substances 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
239000003232 water-soluble binding agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

NO20060313A 2003-07-11 2006-01-20 Saquinavirmesylat oral doseringsform NO20060313L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US48660003P	2003-07-11	2003-07-11
US56820404P	2004-05-05	2004-05-05
PCT/EP2004/007309 WO2005004836A2 (fr)	2003-07-11	2004-07-05	Forme dosifiee orale de mesylate de saquinavir

Publications (1)

Publication Number	Publication Date
NO20060313L true NO20060313L (no)	2006-02-09

Family

ID=34068244

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20060313A NO20060313L (no)	2003-07-11	2006-01-20	Saquinavirmesylat oral doseringsform

Country Status (23)

Country	Link
US (2)	US20050009811A1 (fr)
EP (1)	EP1646369B1 (fr)
JP (2)	JP4608488B2 (fr)
KR (2)	KR100767271B1 (fr)
AU (1)	AU2004255436B2 (fr)
BR (1)	BRPI0412523A (fr)
CA (1)	CA2531486C (fr)
CO (1)	CO5640069A2 (fr)
CR (1)	CR8172A (fr)
EA (1)	EA015349B1 (fr)
EC (1)	ECSP066274A (fr)
IL (1)	IL172890A (fr)
MA (1)	MA27904A1 (fr)
MX (1)	MXPA06000363A (fr)
MY (1)	MY140413A (fr)
NO (1)	NO20060313L (fr)
NZ (1)	NZ544585A (fr)
PA (1)	PA8606001A1 (fr)
PE (1)	PE20050247A1 (fr)
RS (1)	RS20060009A (fr)
TN (1)	TNSN06003A1 (fr)
TW (1)	TWI356711B (fr)
WO (1)	WO2005004836A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7364752B1 (en)	1999-11-12	2008-04-29	Abbott Laboratories	Solid dispersion pharamaceutical formulations
WO2001034119A2 (fr)	1999-11-12	2001-05-17	Abbott Laboratories	Inhibiteurs de cristallisation dans une dispersion solide
RS20060009A (sr) *	2003-07-11	2008-06-05	F.Hoffmann-La Roche Ag.,	Oralni oblik za doziranje sakvinavir mezilata
US8377952B2 (en)	2003-08-28	2013-02-19	Abbott Laboratories	Solid pharmaceutical dosage formulation
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
EP2168573A1 (fr) *	2008-09-30	2010-03-31	LEK Pharmaceuticals D.D.	Formulations contentant d'ézétimibe
CA2873961C (fr)	2012-05-14	2017-09-26	Shionogi & Co., Ltd.	Preparation contenant un derive de 7-carbamoylmorphinane 6,7-insature
WO2020086705A2 (fr) *	2018-10-23	2020-04-30	Eastern Virginia Medical School	Compositions pharmaceutiques et procédés de préparation de formulations posologiques solides à la demande

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4753801A (en) *	1985-10-25	1988-06-28	Eli Lilly And Company	Sustained release tablets
JP2642486B2 (ja) *	1989-08-04	1997-08-20	田辺製薬株式会社	難溶性薬物の超微粒子化法
GB8927913D0 (en) *	1989-12-11	1990-02-14	Hoffmann La Roche	Amino acid derivatives
JP3492688B2 (ja) *	1992-10-09	2004-02-03	鐘淵化学工業株式会社	微細な造粒体の製造方法
TW390813B (en) *	1994-04-29	2000-05-21	Merck & Co Inc	Wet granulation formulation for bisphosphonic acids
US5585115A (en) *	1995-01-09	1996-12-17	Edward H. Mendell Co., Inc.	Pharmaceutical excipient having improved compressability
US5608085A (en) *	1995-02-27	1997-03-04	The University Of Tennessee Research Corporation	Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6177460B1 (en) *	1995-04-12	2001-01-23	The Procter & Gamble Company	Method of treatment for cancer or viral infections
US6039975A (en)	1995-10-17	2000-03-21	Hoffman-La Roche Inc.	Colon targeted delivery system
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6514530B2 (en) *	1997-09-09	2003-02-04	Alza Corporation	Dosage form comprising means for changing drug delivery shape
CA2326349A1 (fr) *	1998-04-09	1999-10-21	F. Hoffmann-La Roche Ag	Procede de production de particules submicroniques par dissolution dans du gaz comprime et des tensioactifs
AU765909C (en) *	1998-12-17	2004-09-23	Alza Corporation	Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US7674480B2 (en) *	2000-06-23	2010-03-09	Teva Pharmaceutical Industries Ltd.	Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
EP1247456A3 (fr) *	2001-02-28	2003-12-10	Pfizer Products Inc.	Compositions pharmaceutiques savoureux pour les animaux domestiques
US20030068356A1 (en) *	2001-07-10	2003-04-10	Pather S. Indiran	Sequential drug delivery systems
RS20060009A (sr) *	2003-07-11	2008-06-05	F.Hoffmann-La Roche Ag.,	Oralni oblik za doziranje sakvinavir mezilata

2004
- 2004-07-05 RS YUP-2006/0009A patent/RS20060009A/sr unknown
- 2004-07-05 JP JP2006519808A patent/JP4608488B2/ja not_active Expired - Lifetime
- 2004-07-05 KR KR1020067000732A patent/KR100767271B1/ko not_active Expired - Lifetime
- 2004-07-05 CA CA2531486A patent/CA2531486C/fr not_active Expired - Lifetime
- 2004-07-05 EA EA200600156A patent/EA015349B1/ru not_active IP Right Cessation
- 2004-07-05 WO PCT/EP2004/007309 patent/WO2005004836A2/fr not_active Ceased
- 2004-07-05 BR BRPI0412523-1A patent/BRPI0412523A/pt not_active IP Right Cessation
- 2004-07-05 NZ NZ544585A patent/NZ544585A/en not_active IP Right Cessation
- 2004-07-05 KR KR1020077016817A patent/KR20070087194A/ko not_active Withdrawn
- 2004-07-05 AU AU2004255436A patent/AU2004255436B2/en not_active Ceased
- 2004-07-05 MX MXPA06000363A patent/MXPA06000363A/es active IP Right Grant
- 2004-07-05 EP EP04763093.4A patent/EP1646369B1/fr not_active Expired - Lifetime
- 2004-07-07 TW TW093120382A patent/TWI356711B/zh not_active IP Right Cessation
- 2004-07-07 PA PA20048606001A patent/PA8606001A1/es unknown
- 2004-07-07 PE PE2004000651A patent/PE20050247A1/es not_active Application Discontinuation
- 2004-07-08 US US10/886,765 patent/US20050009811A1/en not_active Abandoned
- 2004-07-09 MY MYPI20042754A patent/MY140413A/en unknown
2005
- 2005-12-29 IL IL172890A patent/IL172890A/en not_active IP Right Cessation
2006
- 2006-01-05 CR CR8172A patent/CR8172A/es unknown
- 2006-01-06 TN TNP2006000003A patent/TNSN06003A1/en unknown
- 2006-01-06 CO CO06001295A patent/CO5640069A2/es not_active Application Discontinuation
- 2006-01-06 MA MA28709A patent/MA27904A1/fr unknown
- 2006-01-09 EC EC2006006274A patent/ECSP066274A/es unknown
- 2006-01-20 NO NO20060313A patent/NO20060313L/no not_active Application Discontinuation
2008
- 2008-10-31 US US12/262,607 patent/US20090054481A1/en not_active Abandoned
2010
- 2010-08-13 JP JP2010181350A patent/JP2010280707A/ja active Pending

Also Published As

Publication number	Publication date
EA200600156A1 (ru)	2006-08-25
US20050009811A1 (en)	2005-01-13
TW200505504A (en)	2005-02-16
EP1646369B1 (fr)	2019-04-10
KR20070087194A (ko)	2007-08-27
KR20060056320A (ko)	2006-05-24
IL172890A (en)	2013-11-28
BRPI0412523A (pt)	2006-09-19
IL172890A0 (en)	2006-06-11
CA2531486C (fr)	2012-10-02
US20090054481A1 (en)	2009-02-26
WO2005004836A3 (fr)	2005-05-12
CO5640069A2 (es)	2006-05-31
MA27904A1 (fr)	2006-05-02
PE20050247A1 (es)	2005-04-13
HK1089959A1 (en)	2006-12-15
NZ544585A (en)	2008-04-30
TWI356711B (en)	2012-01-21
EA015349B1 (ru)	2011-06-30
WO2005004836A2 (fr)	2005-01-20
RS20060009A (sr)	2008-06-05
EP1646369A2 (fr)	2006-04-19
TNSN06003A1 (en)	2007-10-03
PA8606001A1 (es)	2005-03-03
ECSP066274A (es)	2006-10-25
AU2004255436B2 (en)	2006-11-30
JP4608488B2 (ja)	2011-01-12
MXPA06000363A (es)	2006-03-28
CR8172A (es)	2006-10-04
CA2531486A1 (fr)	2005-01-20
AU2004255436A1 (en)	2005-01-20
MY140413A (en)	2009-12-31
KR100767271B1 (ko)	2007-10-17
JP2010280707A (ja)	2010-12-16
JP2009501694A (ja)	2009-01-22

Legal Events

Date	Code	Title	Description
2017-02-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20080827L (no)	2008-02-15	Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
CY1111470T1 (el)	2015-08-05	Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
HRP20040996B1 (hr)	2010-11-30	Tablete visokog sadržaja lijeka
TW200635897A (en)	2006-10-16	Piperidine derivatives and their use as anti-inflammatory agents
NO20063429L (no)	2006-09-28	Brusende oral opiat doseringsform
MXPA04005877A (es)	2004-09-13	Composiciones farmaceuticas de derivados de taxano oralmente activos con biodisponibilidad mejorada.
EP1741712A3 (fr)	2007-04-04	Nebivolol et son sels pharmaceutiques acceptables, procès pour la preparation et compositions pharmaceutiques de nebivolol
GR1003658B (el)	2001-09-05	Δισκιο μητρας που καθιστα δυνατη την παρατεταμενη απελευθερωση της τριμεταζιδινης μετα χορηγηση δια της στοματικης οδου
NO20034863L (no)	2003-12-30	Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
EP1574215A4 (fr)	2009-07-01	Medicament solide administre par voie orale
NO20074933L (no)	2007-09-28	Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
ATE390128T1 (de)	2008-04-15	Tramadol-formulierungen mit verzögerter freisetzung und 24-stunden-wirksamkeit
NO20061702L (no)	2006-06-19	Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
HUP0203148A2 (hu)	2003-01-28	Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
TNSN06003A1 (en)	2007-10-03	Saquinavir mesylate oral dosage form
UY28457A1 (es)	2005-03-31	Nueva composición
TR200301553A1 (tr)	2005-10-21	İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
ATE389402T1 (de)	2008-04-15	Sedierende nicht-benzodiazepin-formulierungen
SE0301371D0 (sv)	2003-05-09	New Compounds
CO6341613A2 (es)	2011-11-21	Compuestos de indanilo
MY145885A (en)	2012-05-15	Controlled release formulations for oral administration
WO2005115092A3 (fr)	2006-03-23	Composition pharmaceutique orale
CY1116070T1 (el)	2017-02-08	Σκευασματα οξυκωδονης για μια φορα ημερησιως